In this issue of JAMA, the report by Ribas and colleagues1 presents findings from a pooled analysis of 655 patients with advanced melanoma who received pembrolizumab in the KEYNOTE-001 trial, an open-label multicohort study. Of these 655 patients, 173 were included in the randomized trial previously reported by Robert et al,2 135 were included in the nonrandomized cohort previously reported by Hamid et al,3 and 347 were not included in prior reports.
Shailender Bhatia, John A. Thompson. PD-1 Blockade in MelanomaA Promising Start, but a Long Way to Go. JAMA. 2016;315(15):1573–1575. doi:10.1001/jama.2016.4012